Sign in
Taking peoplePhase 4

Methylprednisolone for Moderate to Severe Traumatic Brain Injury

Key facts

Who runs it
Zhangjiagang First People's Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
520 people, planned
Started
29 Mar 2026
Expected to end
31 Jul 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Placebo
  • Methylprednisolone (MP)
Record updated
22 September 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age18-65 years
  • Patients with moderate-to-severe traumatic brain injury whose Glasgow Coma Scale (GCS) score at admission is4-12
  • Study drug must be initiated within12 hours after injury
  • Imaging (CT) demonstrates cerebral contusion, or cerebral contusion with intracerebral hematoma
  • Written informed consent obtained from the subject or legally authorized representative

Who cannot take part

  • Known hypersensitivity to corticosteroids or any contraindication to their use
  • Patients with systemic infectious diseases
  • Patients with a confirmed diagnosis of peptic ulcer
  • Patients with a confirmed diagnosis of systemic autoimmune diseases
  • Any condition that, in the investigator's opinion, renders the patient unsuitable for this study
  • History of diabetes mellitus requiring pharmacological treatment, or capillary blood glucose<2.8 mmol/L or >22.2 mmol/L
  • Shock at admission (systolic blood pressure<90 mmHg for more than30 minutes)
  • Pregnant or lactating women
  • Participation in another clinical trial within the past3 months

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if standard-dose methylprednisolone sodium succinate can improve neurological recovery and safety in adults with moderate to severe traumatic brain injury (TBI). The main questions it aims to answer are:

Read full original descriptionShow less

1. Does adding a 5-day course of methylprednisolone improve overall long-term neurological outcome compared with placebo? 2. Does methylprednisolone reduce 6-month mortality or increase the proportion of patients with good neurological recovery? 3. What medical problems do participants experience when receiving methylprednisolone? Researchers will compare methylprednisolone sodium succinate (2 mg/kg/day intravenously for 5 days) with a matching placebo to see if the steroid improves outcomes beyond standard TBI care.

Participants will:

1. Receive either methylprednisolone or placebo once daily for 5 days, added to guideline-directed standard care. 2. Undergo CT scans and neuro-examinations during hospitalization. 3. Return for follow-up visits at 1 month and 6 months after injury for neurological assessments, safety checks, and questionnaires.

The 2 groups in the trial

  • methylprednisoloneTreatment being tested

    Treatment: Methylprednisolone (MP)

  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Methylprednisolone Sodium Succinate Injection in Patients With Moderate to Severe Traumatic Brain Injury
Criteria questions
Built from NCT07180277, who can take part
Record updated
22 September 2026